Literature DB >> 8613944

Determination and metabolism of dithiol chelating agents. XVII. In humans, sodium 2,3-dimercapto-1-propanesulfonate is bound to plasma albumin via mixed disulfide formation and is found in the urine as cyclic polymeric disulfides.

R M Maiorino1, Z F Xu, H V Aposhian.   

Abstract

The binding of 2,3-dimercapto-1-propanesulfonate (DMPS) in plasma was determined in three healthy young adults after a single 300-mg p.o. dose. By 5 hr after DMPS administration, 62.5% of the total plasma DMPS was bound to proteins. The remainder consisted of nonprotein associated DMPS disulfides (36.6%) and unaltered DMPS (0.9%). Protein-bound DMPS consisted of a DMPS-albumin complex (84%) and a higher molecular weight protein complex (16%), perhaps albumin aggregates. DMPS was released from the isolated DMPS-albumin complex after treatment with dithiothreitol, indicating that it was bound via a disulfide linkage. The half-life of unaltered DMPS was 1.8 hr, whereas that of altered DMPS was 20 hr, suggesting that the DMPS-albumin disulfide complex is stable and that DMPS was released from it slowly. In addition, the biotransformation of OMPS to disulfide forms was extensive. By 9 hr after administration, 10% of the total urinary DMPS was unchanged drug and 90% was altered DMPS. The latter was converted to DMPS by dithiothreitol, indicating that the altered DMPS consisted of disulfides. In 2- to 4-hr urine, DMPS disulfides included cyclic polymeric DMPS disulfides (97%), DMPS-cysteine (1:2) mixed disulfide (2.5%) and acyclic DMPS disulfide (0.5%). The cyclic polymeric DMPS disulfides were present in a major (91.5%) and minor (5.5%) form. DMPS-albumin mixed disulfide and nonprotein DMPS disulfides may prolong the heavy metal mobilizing activity of DMPS and thus may represent reservoirs of DMPS which can be released by disulfide reduction in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613944

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Commentary on "Transdermal DMPS".

Authors:  Charles McKay
Journal:  J Med Toxicol       Date:  2013-03

2.  Kinetic analysis of covalent binding between N-acetyl-L-cysteine and albumin through the formation of mixed disulfides in human and rat serum in vitro.

Authors:  Daisuke Harada; Shinsuku Naito; Masaki Otagiri
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

Review 3.  Arsenic intoxication: general aspects and chelating agents.

Authors:  Geir Bjørklund; Petro Oliinyk; Roman Lysiuk; Md Shiblur Rahaman; Halyna Antonyak; Iryna Lozynska; Larysa Lenchyk; Massimiliano Peana
Journal:  Arch Toxicol       Date:  2020-05-09       Impact factor: 5.153

4.  A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite.

Authors:  Laura-Oana Albulescu; Chunfang Xie; Stuart Ainsworth; Jaffer Alsolaiss; Edouard Crittenden; Charlotte A Dawson; Rowan Softley; Keirah E Bartlett; Robert A Harrison; Jeroen Kool; Nicholas R Casewell
Journal:  Nat Commun       Date:  2020-12-15       Impact factor: 14.919

5.  TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults).

Authors:  Michael Abouyannis; Richard FitzGerald; Mwanajuma Ngama; Hope Mwangudzah; Yvonne K Nyambura; Samson Ngome; Debra Riako; Lawrence Babu; Frida Lewa; Laura Else; Sujan Dily Penchala; Benedict Orindi; Noni Mumba; Betty Kalama; Francis M Ndungu; Ifedayo Adetifa; Saye Khoo; David G Lalloo; Nicholas R Casewell; Mainga Hamaluba
Journal:  Wellcome Open Res       Date:  2022-03-14

6.  Preclinical validation of a repurposed metal chelator as an early-intervention therapeutic for hemotoxic snakebite.

Authors:  Laura-Oana Albulescu; Melissa S Hale; Stuart Ainsworth; Jaffer Alsolaiss; Edouard Crittenden; Juan J Calvete; Chloe Evans; Mark C Wilkinson; Robert A Harrison; Jeroen Kool; Nicholas R Casewell
Journal:  Sci Transl Med       Date:  2020-05-06       Impact factor: 17.956

7.  Treatment of lead and arsenic poisoning in anuric patients - a case report and narrative review of the literature.

Authors:  Chun-Yuan Hsiao; Chip Gresham; Mark R Marshall
Journal:  BMC Nephrol       Date:  2019-10-17       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.